LENZ Therapeutics is a late-stage clinical company developing innovative ophthalmic pharmaceutical products that improve vision. Our lead program is an aceclidine based eye drop designed to restore the loss of near vision associated with presbyopia. Presbyopia impacts almost two billion people globally and more than 120 million people in the US. LENZ Therapeutics is headquartered in San Diego, California, and is backed by multiple blue-chip venture capital investors.  

LENZ Therapeutics

Supply Chain Logistics Coordinator

Sr. Regulatory Operations Specialist

Director, Regulatory CMC

LENZ Therapeutics, Inc.

Lenz Therapeutics’ Earnings Call Highlights Strong Outlook - MSN

LENZ Therapeutics welcomes Mina Ghazizadeh as a Human Resources Generalist. 

Mina attended the University of San Diego, where she played on the women’s soccer team, before earning her graduate degree in Industrial/Organizational Psychology. Most recently, she worked as the People & Culture Specialist with the Portland Trail Blazers. 

Join us in welcoming Mina to the team!

 Lenz Therapeutics Completes Merger With Graphite Bio, Inc. 

LENZ Therapeutics Positioned for Success with LNZ100 Ahead of 2025 PDUFA Date - TipRanks

LENZ Therapeutics welcomes Apple Decena as our new Senior Accountant. Apple brings a strong background in accounting and has over 8 years of experience in Accounts Receivable and Accounts Payable roles. 

Join us in welcoming Apple to the team!

LENZ THERAPEUTICS Earnings Results: $LENZ Reports Quarterly Earnings - Nasdaq

Why LENZ Therapeutics Stock Hit A New 52-Week High Today - Benzinga

Wilson Sonsini Advises LENZ Therapeutics on Completed Merger with Graphite Bio - Wilson Sonsini

 LENZ Therapeutics to Report First Quarter 2025 Financial Results and Recent Corporate Highlights on May 7th, 2025 

Piper Sandler raises LENZ Therapeutics stock to Overweight - Investing.com

LENZ Therapeutics concludes merger with Graphite Bio - Pharmaceutical Technology

 Key Trend In The Eye-Drop And Lubricants Market In 2025: Estrogen-Based Therapy Enhances Menopause Symptom Management 

LENZ Therapeutics Announces Participation in BofA Securities 2025 Health Care Conference - Nasdaq

LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia Trials - Business Wire

LENZ Therapeutics inks deal with Lotus for eye treatment - Investing.com

Patent Challenges Threaten Lenz Therapeutics’ Market Strategy and Financial Stability - TipRanks

LENZ Therapeutics welcomes Fikret Kajoshaj, O.D. as a Medical Science Liaison in the Southeast. 

Fikret graduated from Nova Southeastern University in Fort Lauderdale, Florida where he obtained his Doctor of Optometry degree in 2013. Fikret furthered his training and completed an ocular disease residency at VA Hudson Valley Health Care System in Westchester County, NY. Fikret practiced and gained extensive and valuable clinical experience working at several different ophthalmology clinics and was a Key Opinion Leader for BioTissue in 2016. 
 
Join us in welcoming Fikret to the team!

 LENZ Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights 

Myopia Market to Grow at a Substantial Growth Rate During the Study Period (2019-2032), Predicts DelveInsight | Leading Companies - Nevakar, Vyluma, Bausch & Lomb, Sydnexis, Ocumension, ORA, LENZ Therapeutics - PR Newswire

LENZ Therapeutics welcomes Joseph B. as Regional Sales Director, East Coast. Joseph comes to LENZ with over 10 years of experience rebuilding and leading high performing teams in multiple specialties. Joseph has extensive experience in eye care from his time at Aerie and Alcon. Joseph also brings a diverse business background to LENZ, including CPG sales, Trade Marketing, Retail Sales Management, and multiple Leadership Certifications. His vast experience in Sales Leadership has helped Joe develop an award winning and successful track record over his career including several President Club Awards. These skills will make Joe a key player as we drive towards commercial readiness.

Join us in welcoming Joe to the team!

 Shareholder Alert: Ademi LLP investigates whether Graphite Bio, Inc. has obtained a Fair Price in its transaction with LENZ Therapeutics 

LENZ - LENZ THERAPEUTICS INC Latest Stock News & Market Updates - Stock Titan

LENZ Therapeutics Showcases Revolutionary Eye Drop Treatment at Goldman Sachs, Jefferies Healthcare Events - Stock Titan

LENZ Therapeutics inks exclusive commercialization agreement with Lotus Pharmaceutical - MSN

We are hiring! LENZ Therapeutics is searching for a Sr. Regulatory Operations Specialist. 

This position will be responsible for formatting and publishing regulatory submissions, supporting the implementation and maintenance of our Regulatory Information Management and publishing systems, and ensuring compliance with regulatory submissions requirements throughout the product lifecycle. 

Read the full description and click the link to apply: https://lnkd.in/gWSAjYU3 

Pencils down for Graphite, as gene editing biotech merges into vision-loss-focused Lenz - Fierce Biotech

We are hiring! LENZ Therapeutics is searching for a Quality Specialist (Product Complaint).

This position will support the development, implementation, and maintenance of Quality Systems necessary for the commercial launch and maintenance of ophthalmic combination products. Position focus is supporting Product Complaint process for commercial product.

Read the full job description and click link below to apply: https://lnkd.in/gcrP2apH 

[PRESS RELEASE - LENZ Therapeutics x Laboratoires Théa]
We’re pleased to announce a licensing agreement between LENZ Therapeutics and Laboratoires Théa to bring LNZ100 to the Canadian market. LNZ is a preservative-free ophthalmic solution formulated with aceclidine, which is under evaluation by FDA for the treatment of presbyopia in adult patients.
 
As part of this agreement, Théa will initiate the regulatory process with Health Canada immediately. Our shared goal: to provide eye care professionals with a new treatment option to support patients managing presbyopia—as a complement to glasses or contact lenses.
 
“Canada is an important part of Théa’s international development, and we have been active in the country for several years. Our local team plays an essential role in supporting both patients and eye care professionals. This partnership with LENZ will expand our portfolio with a promising therapy targeting a prevalent condition that affects millions of adults. We see strong potential for LNZ100 in Canada and look forward to initiating the registration process and making the treatment available to Canadian healthcare providers and their patients.” - Jean-Frédéric Chibret, President, Laboratoires Théa.

👉 Read the full press release here: https://bit.ly/407qe8F 
#Thea #LENZTherapeutics #Presbyopia #OphthalmologyInnovation #LNZ100 #NearVision


LENZ stock touches 52-week high at $31.05 amid market optimism - Investing.com

Transcript : LENZ Therapeutics, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 09 - marketscreener.com

A phenomenal day for LENZ Therapeutics in New York, where we hosted a standout Commercial Day at Nasdaq, showcasing the commercial readiness of LNZ100, our potential best-in-class solution in development for presbyopia.

The event featured powerful first-hand insights from both patients and eye care professionals who participated in our Phase 3 clinical trial — bringing real-world impact to life.

We also shared an exciting preview of our commercial strategy and were thrilled to sit down with special guest Tiffani Thiessen, who brought her own voice to the conversation around presbyopia awareness.

We are energized by the overwhelmingly positive feedback. Thank you to everyone who joined us and to the broader LENZ community for your continued support.

#NASDAQ #Presbyopia #EyeCare #TiffaniThiessen

A Sickle Sequel: Matthew Porteus Launches Kamau with Positive Nula-Cell Patient Zero Results - Genetic Engineering & Biotechnology News

 Methods for the treatment of presbyopia 

 LENZ Therapeutics, Inc. (LENZ) Files for 13.07M Share Offering by Selling Stockholders 

 LENZ Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights on March 19, 2025 

View Press Release

LENZ Therapeutics submits NDA for drops to treat presbyopia - Healio

Latham Watkins Advises on US53 5 Private Placement Financing in Connection With LENZ Therapeutics - Latham & Watkins LLP

LENZ Therapeutics, Inc. (LENZ) Is Up 3.37% in One Week: What You Should Know - Yahoo Finance

LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials - Business Wire

We're Hopeful That LENZ Therapeutics (NASDAQ:LENZ) Will Use Its Cash Wisely - Yahoo Finance

 LENZ Therapeutics and Laboratoires Théa Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada 

LENZ Therapeutics welcomes Sam Wilson, CPA as Director, Corporate Controller.

Sam brings over 20 years of accounting and finance experience, including the last 15 years in healthcare technology and life sciences. 
 
Across multiple public, high-growth companies, Sam has built modern finance organizations, enhanced internal controls, and aligned financial operations with commercial objectives. He is passionate about building world-class finance teams and fostering a culture of integrity, accountability, and collaboration.

Join us in welcoming Sam to the team!

 Insider Trading: RA Capital Buys Stock Worth $15M in LENZ Therapeutics - TipRanks.com 

LENZ Therapeutics and Graphite Bio enter merger deal - Pharmaceutical Technology

San Diego’s Lenz Therapeutics snags $83.5M for once-a-day eye drops to replace near-vision glasses - San Diego Union-Tribune

LENZ Therapeutics welcomes Marianna Rabinovich as our new Manager of Payroll and Equity Administration. Marianna joins us with nearly 20 years of experience in the HR and Payroll field, with the last 6 years exclusively in the biotech industry, including Poseida Therapeutics, Zentalis Inc. and Bionano. 

Join us in welcoming Marianna to the team!

LENZ Therapeutics Announces $83.5 Million Series B Financing to Advance its Presbyopia Treatments LNZ100 and LNZ101 and Provides Update on Ongoing Phase 3 Studies - Business Wire

LENZ Therapeutics Finds $83.5M In Series B - socalTech.com

Walter Whitley, OD looks forward to a new solution for presbyopia that will target the iris sphincter. 

"I’m excited about the future of presbyopia, not only for my patients, but for myself. A solution that selectively targets the iris sphincter to improve near vision is something I’m interested in trying, and it’ll be something my patients welcome too."

 A gene editing biotech's struggles end with reverse merger 

LENZ Therapeutics (NASDAQ:LENZ) Trading Down 4.1% - What's Next? - MarketBeat

LENZ Therapeutics May 2025 slides: presbyopia treatment nears FDA decision By Investing.com - Investing.com South Africa

We are hiring! LENZ Therapeutics is searching for a Supply Chain Logistics Coordinator.

This position will support the commercialization of LNZ100 at LENZ. This critical role will focus on coordinating international and domestic shipments and ensuring timely delivery of materials and finished goods through our external manufacturing and warehousing partners. 

Read full description and click link to apply: https://lnkd.in/g3pkQfTv 

Strong Buy Recommendation for LENZ Therapeutics: LNZ100 Poised to Disrupt Presbyopia Market with Best-in-Class Efficacy and Safety - TipRanks

Revolutionary Presbyopia Treatment Developer LENZ Therapeutics Announces Q1 2025 Earnings Date - Stock Titan

Will LENZ's Presbyopia Eye Drop Disrupt the Vision Care Market? Commercial Strategy Reveal Coming - Stock Titan

Wellington Management Group LLP Invests $585,000 in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - MarketBeat

 Lenz Therapeutics management to meet with Piper Sandler 

LENZ Therapeutics and JIXING Announce an Exclusive Greater China License Agreement; RTW to Invest in LENZ Therapeutics - Business Wire

LENZ and Lotus Pharmaceutical collaborate to commercialise presbyopia treatment - MSN

Graphite Erased: LENZ to Merge with Gene Editing Therapy Developer - Genetic Engineering & Biotechnology News

LENZ Therapeutics Announces Positive Topline Data from Phase 2 INSIGHT Trial of LNZ100 and LNZ101 to Treat Presbyopia - Business Wire

 LENZ Therapeutics Announces Completion of Merger with Graphite Bio and Provides Update on Recent Clinical and ... 

 LENZ Therapeutics to Present at Upcoming Investor Conferences 

 Lenz Therapeutics reports Q1 EPS ($3.53), consensus (84c) 

 Lenz Therapeutics, Laboratoires Thea enter license, commercialization agreement 

LENZ Therapeutics Shares Climb After Presbyopia Trial Hits Endpoints - MarketWatch

LENZ Therapeutics Prepares for LNZ100 Launch - TipRanks

LENZ Therapeutics and Lotus partner for LNZ100 distribution in Asia - World Pharmaceutical Frontiers

Taiwan's Lotus Pharma inks $125 M deal with LENZ Therapeutics to commercialise presbyopia treatment - BioSpectrum Asia

LENZ Therapeutics welcomes Kashif Qadeer, O.D. as a Medical Science Liaison in Southern California.

Kashif earned his Doctor of Optometry degree from the Southern California College of Optometry in 2007, following early research experience in ocular medications. He completed a residency in Ocular Disease at the VA Eye Clinic in Las Vegas, then worked in a large ophthalmology practice focusing on LASIK co-management, contact lenses, and clinical research. He later ran a successful two-location private practice in Orange County for over 13 years. Most recently, he returned to the industry side, contributing to clinical research with a major pharmaceutical company.

Join us in welcoming Kashif to the team!

LENZ Therapeutics' LNZ100 Hits FDA Milestone, Reports 74% Success in Phase 3 Trial - StockTitan

LENZ Therapeutics is hiring District Sales Managers! 

The District Sales Manager will have an entrepreneurial mindset and get the opportunity to build their own team to achieve high levels of performance. Great opportunity to join a growing company that is focused on developing a new molecule for the pharmacological treatment of presbyopia. 

Apply utilizing the links below. 

Southern California - https://lnkd.in/gdPtiHx3
Pacific West - https://lnkd.in/gNCAKtiv
Southwest - https://lnkd.in/gxRNZdpC
South Central - https://lnkd.in/g_7uryZv
Midwest - https://lnkd.in/gjXv4BS5
Southeast - https://lnkd.in/g_PeFrba
Great Lakes - https://lnkd.in/gN6fz_nD
Mid-South - https://lnkd.in/gUrQQenV
Northeast - https://lnkd.in/gbjJ7S_J
Mid-Atlantic - https://lnkd.in/gVnsCZ6T


Chris Lievens, OD MS PhD, is motivated by an innovative presbyopia treatment that ensures better results for him and his patients. 
 
"As both a practitioner and a presbyope, I'm anticipating the transformative impact a new solution could have on my own life and the lives of my patients."
 
www.EyeAmSelective.com
#presbyopia 

 LENZ Therapeutics Reports Third Quarter 2024 Financial Results 

We are hiring! LENZ Therapeutics is searching for a Director, Regulatory CMC. 

This role will support the development and successful performance of the CMC regulatory strategy for LENZ Therapeutics. This position is based in San Diego, CA and reports to the VP, Regulatory and Clinical Operations.

Read the full description and click the link to apply: https://lnkd.in/g9UzGBEB 

We are hiring! LENZ Therapeutics is searching for a Sr. Quality Specialist.

This position will support the development, implementation, and maintenance of Quality Systems necessary for the commercial launch and maintenance of ophthalmic combination products.

Other responsibilities for this role include date review and verification, support administration of electronic QMS and Regulatory software(s), product complaint handling and management review program. 

If you are ready to join our team, click link below to apply: https://lnkd.in/gmEr7VXj

 [Video] LENZ Therapeutics on LinkedIn: LENZ Therapeutics welcomes David Choromanski as Vice President of… | 52 ... 

Mark Schaeffer, OD, FAAO believes presbyopia solutions are active and continuously changing. 
 
"The presbyopia market is dynamic. It reflects our patients’ evolving visual needs and their desire for a solution that provides clear vision on their own terms. Vision is dynamic, too—so shouldn’t we consider a solution that mirrors that?"
 
 www.EyeAmSelective.com
 #presbyopia

Earnings call transcript: LENZ Therapeutics Q4 2024 shows innovation drive - Investing.com

Lenz Therapeutics' eye disease drugs meet main goal of late-stage study - ETHealthWorld

 LENZ Therapeutics Stock Gains 16% After Positive Vision-Loss Trial Data 

LENZ Therapeutics and Graphite Bio Announce Merger Agreement - Business Wire

LENZ Therapeutics Stock Is Attractive Before PDUFA (NASDAQ:LENZ) - Seeking Alpha

Lenz Therapeutics Raises $47M in Series A Financing - FinSMEs

View All News

Earnings call transcript: LENZ Therapeutics’ Q1 2025 results show innovation drive - Investing.com

LENZ partners with Lotus to commercialise presbyopia treatment - Pharmaceutical Technology

LENZ Therapeutics and Lotus Pharmaceutical Co., Ltd Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia.

LENZ will receive up to $125 million in upfront, regulatory and commercial milestone payments, as well as tiered, double-digit royalties on future net sales. Lotus will have exclusive development, manufacturing, registration and commercialization rights for LNZ100 for the treatment of presbyopia in the Republic of Korea and certain countries in Southeast Asia, including Thailand, Philippines, Vietnam, Malaysia, Brunei, Indonesia and Singapore.

Read the full press release here: https://lnkd.in/e5QvyN6v

LENZ Therapeutics to Present at Upcoming Investor Conferences - The Manila Times

LENZ Therapeutics Shares Rise After FDA Accepts Application for Potential Eye Condition Treatment - MarketWatch

LENZ Therapeutics announces positive results from Phase 3 CLARITY trials - Optometry Times

 Lenz Therapeutics' eye drop helps improve vision in late-stage study 

Join LENZ Therapeutics at American Optometric Association this week.

Stop by booth #1207 to learn more about the future of presbyopia solutions.

 LENZ Therapeutics and Graphite Bio Announce Merger Agreement 

 Lenz Therapeutics outlines Q4 2025 launch plans for LNZ100 amid FDA review progress 

We are hiring! LENZ Therapeutics is searching for a Supply Chain Logistics Coordinator. 

This position will support the commercialization of LNZ100 at LENZ. This critical role will focus on coordinating international and domestic shipments and ensuring timely delivery of materials and finished goods through our external manufacturing and warehousing partners. 

Read the full description and click the link to apply: https://lnkd.in/g3pkQfTv 


LENZ Therapeutics Hosts Commercial Day for LNZ100 - TipRanks

LENZ Therapeutics

Business:

About: